Douglas V. Faller, MD, PhD

Professor, Medicine

Douglas Faller
617.638.4173
72 E. Concord St Silvio Conte (K)

Biography

Dr. Douglas Faller is a Boston-based physician/scientist with over 15 years of pharmaceutical and biotech experience involving discovery, pre-clinical and clinical development of small molecules for several therapeutic areas, specializing in oncology and hematology, plus over 25 years of academic clinical and laboratory research experience in the fields of drug discovery and development, oncology and hematology, cell and molecular biology, management of professionals, including the programmatic organization of large groups of scientists, and development of research and drug development programs.

Other Positions

  • Active Staff Privileges, Hematology & Medical Oncology, Medicine, Boston Medical Center

Education

  • Harvard University, MD
  • Massachusetts Institute of Technology, PhD
  • Massachusetts Institute of Technology, BS

Publications

  • Published on 3/7/2019

    Faessel H, Nemunaitis J, Bauer TM, Lockhart AC, Faller DV, Sedarati F, Zhou X, Venkatakrishnan K, Harvey RD. Effect of CYP3A inhibitors on the pharmacokinetics of pevonedistat in patients with advanced solid tumours. Br J Clin Pharmacol. 2019 Mar 07. PMID: 30845347.

    Read at: PubMed
  • Published on 1/24/2019

    Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota VK. A retrospective study evaluating treatment patterns and survival outcomes in elderly patients with acute myeloid leukemia treated in the United States with either 7+3 or a hypomethylating agent. Leuk Res. 2019 Mar; 78:45-51. PMID: 30716655.

    Read at: PubMed
  • Published on 12/21/2018

    Faller DV. Response to "Selective PKCd Inhibitor B106 Elicits Uveal Melanoma Growth Inhibitory Effects Independent of Activated PKC Isoforms". ACS Chem Biol. 2019 Jan 18; 14(1):131. PMID: 30525445.

    Read at: PubMed
  • Published on 10/15/2018

    Bell JA, Galaznik A, Blazer M, Shih HC, Farrelly E, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV. Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States. Pharmacoecon Open. 2018 Oct 15. PMID: 30324565.

    Read at: PubMed
  • Published on 7/1/2018

    Moos WH, Faller DV, Glavas IP, Harpp DN, Irwin MH, Kanara I, Pinkert CA, Powers WR, Steliou K, Vavvas DG, Kodukula K. A New Approach to Treating Neurodegenerative Otologic Disorders. Biores Open Access. 2018; 7(1):107-115. PMID: 30069423.

    Read at: PubMed
  • Published on 6/22/2018

    Bell JA, Galaznik A, Blazer M, Farrelly E, Ogbonnaya A, Raju A, Eaddy M, Fram RJ, Faller DV. Transfusion-free interval is associated with improved survival in patients with higher-risk myelodysplastic syndromes engaged in routine care. Leuk Lymphoma. 2019 Jan; 60(1):49-59. PMID: 29932781.

    Read at: PubMed
  • Published on 6/18/2018

    Bell JA, Galaznik A, Farrelly E, Blazer M, Murty S, Ogbonnaya A, Eaddy M, Fram RJ, Faller DV, Kota V. Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. Leuk Res. 2018 08; 71:27-33. PMID: 29944984.

    Read at: PubMed
  • Published on 5/21/2018

    Lockhart AC, Bauer TM, Aggarwal C, Lee CB, Harvey RD, Cohen RB, Sedarati F, Nip TK, Faessel H, Dash AB, Dezube BJ, Faller DV, Dowlati A. Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors. Invest New Drugs. 2019 Feb; 37(1):87-97. PMID: 29781056.

    Read at: PubMed
  • Published on 5/10/2018

    Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV. Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review. Clin Lymphoma Myeloma Leuk. 2018 07; 18(7):e303-e314. PMID: 29802009.

    Read at: PubMed
  • Published on 2/8/2018

    Bell JA, Galaznik A, Huelin R, Stokes M, Guo Y, Fram RJ, Faller DV. Systematic Literature Review of Treatment Options and Clinical Outcomes for Patients With Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2018 04; 18(4):e157-e166. PMID: 29475821.

    Read at: PubMed

View 275 more publications: View full profile at BUMC

View all profiles